Primary mediastinal B-cell lymphoma in the pediatric patient: can a rational approach to therapy be based on adult studies?

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 566-570

  Attias, Dina ^a   Hodgson, David ^b   Weitzman, Sheila ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Chemotherapy; Pediatric primary mediastinal B cell lymphoma; Radiation therapy; Rituximab

Indexed keywords

BLEOMYCIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME 9P; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; EVENT FREE SURVIVAL; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; INVOLVED FIELD RADIATION THERAPY; LARGE CELL LYMPHOMA; MAL GENE; ONSET AGE; OVERALL SURVIVAL; PDL2 GENE; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REED STERNBERG CELL; REVIEW; SCINTIGRAPHY; SEX DIFFERENCE; SNFT GENE; TREATMENT OUTCOME; TREATMENT PLANNING; ADULT; CHILD; CLASSIFICATION; MEDIASTINUM TUMOR; METHODOLOGY; PATHOLOGY; PEDIATRICS;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MEDIASTINAL NEOPLASMS; PEDIATRICS;

EID: 63649114607     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21821     Document Type: Review

References (38)

1. Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of hematopoetic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 175-178.
2. Miller JB, Variakojis D, Bitran JD, et al. Diffuse histiocytic lymphoma with sclerosis: A clinicopathologic entity frequently causing superior venacaval obstruction. Cancer 1981;47:748- 756.
3. Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: A B-cell tumour of probable thymic origin. Histopathology 1986; 10:379- 390.
4. Popov S, Moldenhauer G, Wotschke B, et al. Target sequence accessibility limits activation-induced cytidine deaminase activity in primary -cell lymphoma. Cancer Res 2007;67:6555-6564.
5. Savage KJ. Primary mediastinal large B-cell lymphoma. Oncolo- gist2006;11:488 -495.
6. Boleti E, Johnson PWM. Primary mediastinal B-cell lymphoma. Hematol Oncol 2007;25:157-163.
7. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871 -3879.
8. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851 -862.
9. Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006;108:311 -318.
10. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of anovelMBL cell line. Genes Chromosomes Cancer 2001;30:393-401.
11. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996;87:1571 -1578.
12. Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007;46:406-415.
13. Lam LT, David RE, Pierce J, et al. Small molecule inhibitors of IicfS kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
14. Wessendorf S, Barth TFE, Viardot A, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: An analysis of 37 tumor samples using high resolution genomic profiling (array-CGH). Leukemia 2007;21:2463 -2469.
15. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007;109:271 -280.
16. StejskalovaE, JarasovaM, KabickovaE, etal. Priamry mediastinal (thymic) large B-cell lymphoma with a der(14)t(8;14) (q24;q32) and a translocation of MYC to the derivative chromosome 14 with a deleted IgH locus. Cancer Genet Cytogenet 2006;170:158-162.
17. Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: Clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995;89:780-789.
18. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 non-mediastinal large B-cell lymphomas, a GELA (''Groupe d'EtudedesLymphomes de l'Adulte'') study. Am J Surg Pathol 1996;20:877-888.
19. SeidemannK, TiemannM,LauterbachI, etal. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: Treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 2003;21:1782-1789.
20. Gerrard M, Cairo MS, Weston C, et al. Primary mediastinal large B-cell lymphoma: Results of the FABLMB 96 study. Pediatr Blood Cancer 2004;43:361 -362.
21. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicenter Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372- 376.
22. Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: Clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995;89:780-789.
23. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258-1264.
24. Mazzarotto R, Boso C, Vianello F, et al. Primary mediastinal large B-cell lymphoma: Results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys 2007;68:823-829.
25. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Brit J Haematol 2005;131:39-49.
26. Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large B-cell lymphoma with sclerosis: A clinical study of 21 patients. J Clin Oncol 1990;8:804-808.
27. Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol 1986;10:176-191.
28. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol 2006;17:123-130.
29. Hamlin PA, Carol S, Portlock CS, et al. Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691-699.
30. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 2002;99: 2685-2693.
31. Patte C, Reiter A, Roselen A, et al. Primary mediastinal large B-cell lymphoma (PMBCL) in children/adolescence. Data of European and American groups. Pediatr Blood Cancer 2006;46:844. A31.
32. Patte C, Auperin A, Gerrard M, et al. for the FAB/LMB96 International Study Committee: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007;109:2773 -2780.
33. Siracusano L, Balzarotti M, Magagnoli M, et al. Primary mediastinal B-cell lymphoma with sclerosis. A report of 11 cases treated with intensified CHOP plus radiotherapy. Am J Hematol 2005;78:313.
34. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91:850-854.
35. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475 -481.
36. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's Disease. J Clin Oncol 2007;25:3902-3907.
37. Edeline V, Bonardel G, Brisse H, et al. Prosepctive study of 18F-FDG-PET in pediatric mediastinal lymphoma: A single center experience. Leuk Lymphoma 2007;48:823 - 826.
38. 67-scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 2007; 48:699-707.